Skip to content
Open access

Bifidobacterium animalis subsp. lactis BL-99 ameliorates age-related intestinal hypomotility in older adults: a randomized controlled trial

Oct 2026 · Nature Communications · Vol 17 · 0 citations · 60 references
Medicine

TL;DR

A microbiota-BA-SMC signaling axis that ameliorates age-related intestinal hypomotility is established and positioning both BL-99 and TCDCA as precision therapeutic candidates targeting SMC-related dysmotility is positioned.

Abstract

The decay of smooth muscle contractility is a major trigger of aging-related intestinal hypomotility, which imposes a substantial healthcare burden. Despite this, effective targeted therapy for this condition remains unavailable. Here, we identified the probiotic Bifidobacterium animalis subsp. lactis BL-99 as a microbiota modulator that restores gut motility through the bile acid (BA)-mediated rescue of smooth muscle contractile function. In a randomized, double-blind clinical trial (ChiCTR2300077583, with the primary endpoint of whole-gut transit time [WGTT], and secondary endpoints including bowel movement frequency, symptom severity, and quality-of-life measures) and naturally aged mouse models, BL-99 intervention significantly reduced the WGTT and concurrently remodeled the gut microbiota. This suppressed bile salt hydrolase-expressing bacteria, which preserved conjugated BA pools, including taurochenodeoxycholic acid (TCDCA). Mechanistic investigations revealed that BL-99 was associated with enhanced expression of the serum response factor (SRF)–myocardin (Myocd) transcriptional axis in colonic smooth muscle cells (SMCs), restoring contractile apparatus components (e.g., α-SMA, SM-MHC). Crucially, TCDCA administration recapitulated BL-99 regulation of intestinal SMC contractile protein expression by inhibiting the PI3K/AKT pathway. Our findings established a microbiota-BA-SMC signaling axis that ameliorates age-related intestinal hypomotility, positioning both BL-99 and TCDCA as precision therapeutic candidates targeting SMC-related dysmotility. Here, in a randomized, double-blind clinical trial in older adults, the authors show that probiotic Bifidobacterium animalis subsp. lactis BL-99 intervention reduces whole-gut transit time and remodels the gut microbiota suppressing bile salt hydrolase-expressing bacteria, further revealing a mechanistic role of taurochenodeoxycholic acid in the phenotype.

Read PDF

Similar papers

Open access Oct 2026

Live combined bifidobacterium attenuates rivaroxaban-associated colonic bleeding in mice: evidence for a substantial gut microbiota-dependent component

Rivaroxaban, a direct oral anticoagulant (DOAC), is widely prescribed for the prevention and treatment of thromboembolic disorders. However, its use is associated with an increased risk of gastrointestinal bleeding, the mechanisms of which remain incompletely understood. Effective strategies to relief such bleeding are...

Xiao-Wen Chen, Yu-Ze Lin, You-Qi Huang et al. · 0 citations
Open access Oct 2026

Pediococcus acidilactici PA53 Supplementation Improves Stool Form and Modulates Gut Microbiota and Inflammatory Responses in Adults With Functional Constipation: A Randomized, Double‐Blind, Placebo‐Controlled Trial

ABSTRACT This study aimed to evaluate the efficacy and safety of Pediococcus acidilactici ( P. acidilactici ) PA53 in adults with functional constipation. In this randomized, double‐blind, placebo‐controlled trial, 87 adults with functional constipation were assigned to receive either P. acidilactici PA53 (3.0 × 1010 C...

Yu-Han Xia, Yong-Mei Cai, Yong-Wei Zhang et al. · 0 citations
Oct 2026

Bifidobacterium animalis subsp. lactis ProSci-246 Protects Mice from DSS-induced Inflammatory Bowel Disease by Modulating the Intestinal Metabolite Profile in Mice.

ProSci-246 significantly alleviated DSS-induced colitis, as shown by significantly higher 30-day body weight, colon length-to-weight ratio, and serum anti-inflammatory factor levels, along with significantly lower Disease Activity Index (DAI) scores and serum pro-inflammatory factor levels in the ProSci-246 group compa...

Wen-Kang Zhai, Yang-Bo Jiao, Hui-Min Chen et al. · 0 citations
Open access Oct 2026

Preventive administration of Bifidobacterium animalis subsp. lactis HEM20–01 attenuates the development of atopic dermatitis-like inflammation in mice, along with gut microbial and succinate alterations

Background Atopic dermatitis (AD) is a chronic inflammatory skin disorder frequently accompanied by gut dysbiosis and neurobehavioral comorbidities, but the microbial metabolites mediating gut–skin crosstalk remain unclear. We investigated whether preventive administration of Bifidobacterium animalis subsp. lactis HEM2...

Young-Su Jang, Hyeongjin Na, Hyo-Jin Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.